Header Logo

Connection

VIDYARATNA FLEETWOOD to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications VIDYARATNA FLEETWOOD has written about Cost-Benefit Analysis.
VIDYARATNA FLEETWOOD
Connection Strength
0.023
Cost-Benefit Analysis
  1. Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation. Transplant Proc. 2015 Mar; 47(2):478-84.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.